In today's healthcare, U.S. Central Venous Catheter Market performs a critical function. These catheters enable convenient intravenous fluid, blood product, drug, and parenteral nutrition administration, as well as hemodialysis access and hemodynamic monitoring. They are utilized for longer-term therapies in a variety of conditions, including cancer (chemotherapy) and end-stage renal disease (dialysis).
The central venous catheter market is predicted to rise due to the rising prevalence of cancer.
U.S. Central Venous Catheter Market is a group of chronic diseases characterized by uncontrollable cell proliferation. According to the National Cancer Institute, there are more than 100 different forms of cancer that can be classified based on the cells that make them up. Cancer is the second most prevalent cause of mortality in the United States, accounting for approximately one out of every four fatalities, according to the American Cancer Society.
According to the National U.S. Central Venous Catheter Market for Chronic Disease Prevention and Health Promotion, chronic kidney disease affects roughly 30 million people in the United States or 15% of the adult population.
Cancer is the second biggest cause of illness and mortality globally, according to the World Health Organization (WHO), with around 14 million new cases documented in 2012. Furthermore, the WHO estimates that by 2030, the number of new cases would have increased by roughly 70%. Cancer claimed the lives of 8.8 million people globally in 2015.
The central venous catheter market in the United States is predicted to develop as industry participants adopt more collaborative methods.
Because industry participants are increasingly adopting collaborative methods, the central venous catheter market in the United States is predicted to develop significantly. For example, in 2017, Becton, Dickinson, and Company purchased C.R. Bard, Inc., creating a new health care sector leader with annualized revenue of nearly US$ 16 billion. Similarly, in July 2018, B.Braun Melsungen AG purchased NxStage Medical, Inc.'s bloodlines business. B. Braun Melsungen AG's dialysis business benefited from this transaction.
Players to Watch
AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation are some of the major companies in the US central venous catheter market.
Source Link:https://bit.ly/3pYw2i6
Source Link:https://bwnews.pr/3DNXeEX
0 Comments